FAQs About Roche’s Risdiplam Compassionate Use Programme (CUP) for Those who have SMA Type 1 or 2

21 August 2020

These cover who may be eligible for access, the application process and how the treatment programme will work. They also cover some other questions that have been asked about what future access routes to risdiplam there may be for those who have Type 3. They have been checked for accuracy by Roche.

Read the FAQs